Related Experiment Video

Updated: Jul 15, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Smad4 and ERK2 stimulated by transforming growth factor beta1 in rhabdomyosarcoma

Hua Guo1, Hong-ying Zhang, Shou-li Wang

  • 1Department of Pathology, Peking University First Hospital, Beijing 100034, China.

Chinese Medical Journal
|April 19, 2007
PubMed
Abstract

Insights

Transforming growth factor beta (TGF-beta) activates the MAPK (ERK2) pathway in rhabdomyosarcoma (RMS) cells, independent of Smad4. This suggests alternative signaling routes in RMS development and metastasis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Transforming growth factor beta (TGF-beta) regulates cell processes but its role in soft tissue sarcoma is understudied.
  • Previous research suggests non-Smad pathways are crucial for human embryonal rhabdomyosarcoma (RMS) growth.

Purpose of the Study:

  • To investigate the expression and functional relationship of extracellular signal-regulated kinase 2 (ERK2) and Smad4 in human RMS.
  • To determine the effect of TGF-beta1 on the MAPK (ERK2) pathway in RMS cells.

Main Methods:

  • Analyzed ERK2 and Smad4 expression (mRNA and protein) in RD cells and human RMS tissues using RT-PCR, immunofluorescence, and immunohistochemistry.
  • Stimulated RD cells and skeletal myoblasts with TGF-beta1.
  • Performed 6-70 month follow-up on 50 RMS and 23 normal skeletal muscle specimens.

Main Results:

  • Human RMS tissues and RD cells exhibited higher ERK2 and Smad4 expression than normal controls.
  • TGF-beta1 stimulation increased ERK2 expression and nuclear translocation, activating the MAPK (ERK2) pathway.
  • No correlation was found between ERK2 and Smad4 protein levels; overexpression did not impact prognosis.

Conclusions:

  • TGF-beta1 signaling in RMS involves the MAPK (ERK2) pathway, potentially independent of Smad4.
  • Complex interactions between TGF-beta1/Smads and MAPK pathways may influence RMS tumor development, invasion, and metastasis.

More Related Videos

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.